Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "Staphylococcal Infections - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Staphylococcal Infections - Pipeline Insight, 2024" report provides comprehensive insights about 22+ companies and 23+ pipeline drugs in Staphylococcal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Staphylococcal Infections pipeline landscape is provided which includes the disease overview and Staphylococcal Infections treatment guidelines. The assessment part of the report embraces, in depth Staphylococcal Infections commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Staphylococcal Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Staphylococcal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Staphylococcal Infections.
Staphylococcal Infections Emerging Drugs Chapters
This segment of the Staphylococcal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Staphylococcal Infections Emerging Drugs
Ceftobiprole: Basilea Pharmaceutica
Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria. The drug is in the Registration stage of development for the treatment of patients with Staphylococcal Infections.
ALS-4: Aptorum
ALS-4 is a novel first-in-class orally administered small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA. ALS-4 targets the antimicrobial resistant properties of the bacteria and is believed to render the bacteria highly susceptible to the host's immune clearance. ALS-4 is targeted for potential administration on a standalone or on a combination basis with other existing antibiotics such as vancomycin. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Staphylococcal Infections.
HY-133: HYpharm GmbH
HYpharm GmbH and a consortium funded by the DZIF are cooperating in the area of production and preclinical development of the phage lysin protein HY-133. A joint early clinical development for the nasal decolonization of Staphylococcus aureus is specifically planned. The drug is currently in the preclinical stage of development for the treatment of Staphylococcal Infections.
Staphylococcal Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Staphylococcal Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Staphylococcal Infections drugs.
Staphylococcal Infections: Therapeutic Assessment
Major Players in Staphylococcal Infections
There are approx. 22+ key companies which are developing the therapies for Staphylococcal Infections. The companies which have their Staphylococcal Infections drug candidates in the most advanced stage, i.e. Registration include, Basilea Pharmaceutica.
Key Questions
- How many companies are developing Staphylococcal Infections drugs?
- How many Staphylococcal Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Staphylococcal Infections?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Staphylococcal Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Staphylococcal Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- HYpharm GmbH
- Aptorum
- Basilea Pharmaceutica
- Destiny Pharma
- Technophage
- Mabwell (Shanghai) Bioscience
- Armata Pharmaceuticals
- Trellis Bioscience
- Lytix Biopharma
- Locus Biosciences
Key Products
- HY-133
- ALS-4
- Ceftobiprole
- XF-73
- TP-102
- 9MW1411
- AP-SA02
- TRL1068
- LTX-109
- LBP-SA01
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Staphylococcal Infections Report Insights
- Staphylococcal Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Staphylococcal Infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jwcndt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
